Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Medicis, a specialty pharmaceutical company, has received another notice of allowance from the US Patent and Trademark Office for a US patent application related to Solodyn in 90mg tablet form.
Subscribe to our email newsletter
The newly allowed claims include subject matter covering a controlled-release oral dosage form of minocycline to treat acne.
Solodyn has one issued US patent, which expires in 2018, related to the use of the Solodyn unique dissolution rate, and earlier this month received a notice of allowance on a second application. The company has a number of US patent applications associated with the Solodyn program on file at the US Patent and Trademark Office (USPTO).
Jonah Shacknai, chairman and CEO of Medicis, said: “We are pleased to announce another notice of allowance by the USPTO. This represents an important element of maintaining the Solodyn franchise. These allowed patent claims, when issued, will enhance the intellectual property protection of our Solodyn brand.”